Resistin Is an Inflammatory Marker of Atherosclerosis in Humans

Background—Resistin, a plasma protein, induces insulin resistance in rodents. Recent reports suggest that circulating levels of resistin are elevated in obese and insulin-resistant rodents and humans. Whereas rodent resistin is made in adipocytes, macrophages are a major source of human resistin. Given the convergence of adipocyte and macrophage function, resistin may provide unique insight into links between obesity, inflammation, and atherosclerosis in humans. Methods and Results—We examined whether plasma resistin levels were associated with metabolic and inflammatory markers, as well as with coronary artery calcification (CAC), a quantitative index of atherosclerosis, in 879 asymptomatic subjects in the Study of Inherited Risk of Coronary Atherosclerosis. Resistin levels were positively associated with levels of inflammatory markers, including soluble tumor necrosis factor-&agr; receptor-2 (P<0.001), interleukin-6 (P=0.04), and lipoprotein-associated phospholipase A2 (P=0.002), but not measures of insulin resistance in multivariable analysis. Resistin levels also were associated (odds ratio and 95% confidence interval in ordinal regression) with increasing CAC after adjustment for age, sex, and established risk factors (OR, 1.23 [CI, 1.03 to 1.52], P=0.03) and further control for metabolic syndrome and plasma C-reactive protein (CRP) levels (OR, 1.25 [CI, 1.04 to 1.50], P=0.01). In subjects with metabolic syndrome, resistin levels further predicted CAC, whereas CRP levels did not. Conclusions—Plasma resistin levels are correlated with markers of inflammation and are predictive of coronary atherosclerosis in humans, independent of CRP. Resistin may represent a novel link between metabolic signals, inflammation, and atherosclerosis. Further studies are needed to define the relationship of resistin to clinical cardiovascular disease.

[1]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[2]  M. Reilly,et al.  An Inflammatory Cascade Leading to Hyperresistinemia in Humans , 2004, PLoS medicine.

[3]  Kazuya Yamada,et al.  The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. , 2004, American journal of human genetics.

[4]  C. Mantzoros,et al.  Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. , 2004, Diabetes care.

[5]  M. Reilly,et al.  Measures of Insulin Resistance Add Incremental Value to the Clinical Diagnosis of Metabolic Syndrome in Association With Coronary Atherosclerosis , 2004, Circulation.

[6]  A. Localio,et al.  Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[7]  R. Ahima,et al.  Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. , 2004, Diabetes.

[8]  Michael Pignone,et al.  Using the coronary artery calcium score to predict coronary heart disease events: a systematic review and meta-analysis. , 2004, Archives of internal medicine.

[9]  C. Gutiérrez,et al.  Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. , 2004, Obesity research.

[10]  L. J. Hardies,et al.  Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients , 2004, International Journal of Obesity.

[11]  P. A. Tataranni,et al.  High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. , 2004, Diabetes.

[12]  A. Localio,et al.  Coronary artery calcification and cardiovascular risk factors: impact of the analytic approach. , 2004, Atherosclerosis.

[13]  M. Lazar,et al.  Regulation of Fasted Blood Glucose by Resistin , 2004, Science.

[14]  R. Nagai,et al.  Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. , 2004, Biochemical and biophysical research communications.

[15]  Stephen A. Smith,et al.  Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. , 2003, The Journal of clinical endocrinology and metabolism.

[16]  R. Considine,et al.  Serum resistin (FIZZ3) protein is increased in obese humans. , 2003, The Journal of clinical endocrinology and metabolism.

[17]  J. Eisen,et al.  Comparative studies of resistin expression and phylogenomics in human and mouse. , 2003, Biochemical and biophysical research communications.

[18]  J. Chan,et al.  Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  P. Sucharda,et al.  Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. , 2003, European journal of endocrinology.

[20]  A. Localio,et al.  C-Reactive Protein and Coronary Artery Calcification: The Study of Inherited Risk of Coronary Atherosclerosis (SIRCA) , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Reilly,et al.  The Metabolic Syndrome: More Than the Sum of Its Parts? , 2003, Circulation.

[22]  H. Tilg,et al.  Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. , 2003, Biochemical and biophysical research communications.

[23]  P. Scherer,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0580 Minireview: The Adipocyte—At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis , 2022 .

[24]  S. Haffner.  Insulin resistance, inflammation, and the prediabetic state. , 2003, The American journal of cardiology.

[25]  S. Verma,et al.  Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction , 2003, Circulation.

[26]  T. Saruta,et al.  Correlation between serum resistin level and adiposity in obese individuals. , 2003, Obesity research.

[27]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[28]  Kiang Liu,et al.  Electron-Beam Tomography Coronary Artery Calcium and Cardiac Events: A 37-Month Follow-Up of 5635 Initially Asymptomatic Low- to Intermediate-Risk Adults , 2003, Circulation.

[29]  C. Mantzoros,et al.  Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. , 2003, The Journal of clinical endocrinology and metabolism.

[30]  A. Stütz,et al.  The Th2 Cell Cytokines IL-4 and IL-13 Regulate Found in Inflammatory Zone 1/Resistin-Like Molecule α Gene Expression by a STAT6 and CCAAT/Enhancer-Binding Protein-Dependent Mechanism , 2003, The Journal of Immunology.

[31]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[32]  S. Bahouth,et al.  Resistin release by human adipose tissue explants in primary culture. , 2003, Biochemical and biophysical research communications.

[33]  L. Rossetti,et al.  Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. , 2003, The Journal of clinical investigation.

[34]  Joanna D. Holbrook,et al.  Resistin is expressed in human macrophages and directly regulated by PPARγ activators , 2003 .

[35]  B. Miskie,et al.  Elevated Serum C-Reactive Protein and Free Fatty Acids Among Nondiabetic Carriers of Missense Mutations in the Gene Encoding Lamin A/C (LMNA) With Partial Lipodystrophy , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[36]  J. Heyn,et al.  Plasma Resistin Levels in Patients with Type 1 and Type 2 Diabetes Mellitus and in Healthy Controls , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[37]  Hui-Ling Chen,et al.  Lipopolysaccharide increases resistin gene expression in vivo and in vitro , 2002, FEBS letters.

[38]  S. Kumar,et al.  Resistin, central obesity, and type 2 diabetes , 2002, The Lancet.

[39]  H. Sul,et al.  A Cysteine-rich Adipose Tissue-specific Secretory Factor Inhibits Adipocyte Differentiation* , 2001, The Journal of Biological Chemistry.

[40]  M. Lazar,et al.  The hormone resistin links obesity to diabetes , 2001, Nature.

[41]  M. Lazar,et al.  A family of tissue-specific resistin-like molecules. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Little,et al.  Insulin resistance and substrate utilization in human endotoxemia. , 2000, The Journal of clinical endocrinology and metabolism.

[43]  F. Peale,et al.  FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family , 2000, The EMBO journal.

[44]  D. Moller.  Potential Role of TNF-α in the Pathogenesis of Insulin Resistance and Type 2 Diabetes , 2000, Trends in Endocrinology & Metabolism.

[45]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[46]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[47]  D. Rader,et al.  Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. , 1999, Mayo Clinic proceedings.

[48]  W. Edwards,et al.  Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. , 1994, The American journal of cardiology.

[49]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.

[50]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[51]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[52]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[53]  K. Park,et al.  Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. , 2004, The Journal of clinical endocrinology and metabolism.

[54]  T. Yoshikawa,et al.  Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[55]  P. Murdock,et al.  Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. , 2003, Biochemical and biophysical research communications.

[56]  T. Forst,et al.  Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. , 2003, Clinical laboratory.

[57]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[58]  D. Moller.  Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. , 2000, Trends in endocrinology and metabolism: TEM.

[59]  W A Buurman,et al.  Tumor necrosis factor: function, release and clearance. , 1996, Critical reviews in immunology.